TABLE 2.
Blood biochemistry1
| Parameter | Placebo | NR | Change | P value |
|---|---|---|---|---|
| Glucose, mmol/L | 5.48 ± 0.14 | 5.44 ± 0.13 | −0.04 ± 0.10 | 0.70 |
| Triglycerides, mmol/L | 1.57 ± 0.35 | 1.63 ± 0.38 | 0.06 ± 0.08 | 0.24 |
| Total cholesterol, mmol/L | 5.54 ± 0.30 | 5.55 ± 0.35 | 0.01 ± 0.11 | 0.99 |
| HDL-C, mmol/L | 1.32 ± 0.12 | 1.32 ± 0.09 | −0.00 ± 0.04 | 0.99 |
| LDL-C,2 mmol/L | 3.42 ± 0.18 | 3.37 ± 0.17 | −0.05 ± 0.07 | 0.52 |
| sE-selectin,3 pg/mL | 32,726 ± 5298 | 34,765 ± 4354 | 686 ± 2068 | 0.99 |
| sP-selectin,3 pg/mL | 21,428 ± 3662 | 26,645 ± 4065 | 2624 ± 3739 | 0.58 |
| ICAM-1,3 pg/mL | 92,493 ± 19,326 | 129,236 ± 34,547 | 35,350 ± 27,518 | 0.58 |
| TNF-α,3 pg/mL | 29.80 ± 6.38 | 31.85 ± 6.14 | 2.70 ± 1.97 | 0.22 |
| IL-1α,3 pg/mL | 2.11 ± 0.35 | 1.61 ± 0.28 | −0.57 ± 0.24 | 0.06 |
| IL-4,3 pg/mL | 8.04 ± 1.03 | 8.86 ± 1.41 | 0.71 ± 3.63 | 0.69 |
| IL-12p70,3 pg/mL | 76.07 ± 2.73 | 78.89 ± 3.02 | 1.94 ± 2.82 | 0.81 |
| IL-17α,3 pg/mL | 6.36 ± 1.36 | 7.95 ± 2.09 | 1.76 ± 1.02 | 0.16 |
| CXCL10,3 pg/mL | 3.71 ± 0.55 | 3.39 ± 0.50 | −0.61 ± 0.40 | 0.22 |
| CCL2,3 pg/mL | 127.39 ± 24.54 | 144.34 ± 47.86 | 21.42 ± 40.12 | 0.69 |
| CCL3,3 pg/mL | 15.42 ± 8.59 | 17.04 ± 10.39 | 2.43 ± 1.92 | 0.30 |
| CCL4,3 pg/mL | 23.89 ± 5.98 | 28.49 ± 7.51 | 4.52 ± 4.45 | 0.38 |
1Values are means ± SEs. P values are derived from the analysis of the mean within-person changes and the SE of the within-group changes. Blood samples were taken in week 6 of NR supplementation and placebo after an overnight fast. CCL, CC chemokine ligand; CXCL, CXC chemokine ligand; HDL-C, HDL cholesterol; ICAM-1, intercellular adhesion molecule 1; LDL-C, LDL cholesterol; NR, nicotinamide riboside.
2 n = 12.
3 n = 7.